Lawyers representing pharmaceutical companies in litigation over off-label marketing may want to read up on the U.S. Supreme Court’s decision in the so-called “Stolen Valor” case, former U.S. Solicitor General Paul Clement said Monday.

Clement was speaking to the Federalist Society in Philadelphia for his annual review of the high court’s term and noted there is one issue the court is often consistent on: First Amendment cases involving free speech.